Who are pentoxifylline (Trental SR®)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Pentoxifylline sustained-release tablets, Theophylline Anhydrous Oral Tablet, pentoxifylline (PTX).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pentoxifylline-trental-sr.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

pentoxifylline (Trental SR®) — Competitive Intelligence Brief

pentoxifylline (Trental SR®) (pentoxifylline (Trental SR®)) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: xanthine derivative. Area: Cardiovascular.

phase 3 xanthine derivative Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

pentoxifylline (Trental SR®) (pentoxifylline (Trental SR®)) — Al-Azhar University. Pentoxifylline increases blood flow by improving red blood cell flexibility and reducing blood viscosity.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
pentoxifylline (Trental SR®) TARGET	pentoxifylline (Trental SR®)	Al-Azhar University	phase 3	xanthine derivative
Pentoxifylline sustained-release tablets	Pentoxifylline sustained-release tablets	Beijing Tiantan Hospital	marketed	Methylxanthine derivative; phosphodiesterase inhibitor	Phosphodiesterase
Theophylline Anhydrous Oral Tablet	Theophylline Anhydrous Oral Tablet	Damanhour Teaching Hospital	marketed	Nonselective phosphodiesterase inhibitor; xanthine derivative	Phosphodiesterase enzymes (nonselective); adenosine receptors (antagonist)
pentoxifylline (PTX)	pentoxifylline (PTX)	Case Western Reserve University	phase 3	Methylxanthine derivative; hemorheological agent	Phosphodiesterase (non-selective); adenosine receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (xanthine derivative class)

Al-Azhar University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). pentoxifylline (Trental SR®) — Competitive Intelligence Brief. https://druglandscape.com/ci/pentoxifylline-trental-sr. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab